The loss of CAR-T in blood is a problem for oncologists making them more difficult to personalize the treatment.
Molecular imaging is a non-invasive solution for providing information about CAR-T therapy to oncologists.
PET radiotracers are contrast agents that allow molecular imaging using a medical PET scanner.
Radiotracers are compounds that combine the precision of specific binding molecules (ligand) with the radioactive properties of isotopes.
Radiotracers consists of three parts:
– Ligand that functions as a specific carrier.
– Isotope gives radiodiagnostic applications.
– Linker that binds the ligand to the isotope.
Radiotracers are a crucial element for personalized nuclear medicine and precision oncology.
YSOTOPE designs new targeted radiotracers for monitoring CAR-T cells.
YSOTOPE uses specific ligands to design co-diagnostic radiotracers to monitor CAR-T cells inside the patient’s body.
Using nuclear imaging YSOTOPE’s radiotracers provide information about CAR-T treatment:
YSOTOPE radiotracer provides high-value information about CAR-T treatment.
Co-development through partnerships in R&D projects.
Test the radiopharmaceutical in animals and humans.
Ensure assets exclusivity by combining different IPR tools.
Patents monetization through IP licensing and sublicensing.
YSOTOPE is a Spanish company founded in 2022 by a team with experience in deep tech entrepreneurship and radiochemistry.
YSOTOPE is a Spanish company founded in 2022 by a team with experience in deeptech entrepreneurship and radiochemistry.
Strategy and management
YSOTOPE is also counting on expert entities as strategic support
YSOTOPE is also counting on expert entities as strategic support.
Scientific
Business
REFERENCES:
Icons: https://www.flaticon.com/
Background images: https://unsplash.com/
Radiopharmaceutical diagram: https://smart.servier.com/
Affinity and metabolism & Preclinical studies images: https://app.biorender.com/